Unicycive Therapeutics — oxylanthanum carbonate $UNCY
for hyperphosphatemia in adults with chronic kidney disease on dialysis
for hyperphosphatemia in adults with chronic kidney disease on dialysis
Hyperphosphatemia is a condition where phosphate builds up in the blood, usually because damaged kidneys can no longer filter it out; many people feel no symptoms, but others develop calcium deposits in soft tissue, and low blood calcium can cause muscle spasms. Oxylanthanum carbonate is an oral phosphate binder: it travels through the gut, binds phosphate from food, and carries it out in the stool instead of letting it reach the bloodstream. Because dialysis removes phosphate only between meals, this drug may help keep levels lower and could reduce the calcium deposits and spasms that come with the disorder.
The goal of this clinical study is to test the tolerability of oxylanthanum carbonate (OLC) in patients with chronic kidney disease on hemodialysis and have hyperphosphatemia (too much phosphorus in their blood). The main question it aims to answer is whether patients taking OLC for hyperphosphatemia are able to tolerate the drug
Source: ClinicalTrials.gov